Science Selection August 2014 | Volume 122 | Issue 8
Fire in the Belly? Sulfur-Reducing Gut Microbes Fuel Arsenic Thiolation
Carol Potera, based in Montana, has written for EHP since 1996. She also writes for Microbe, Genetic Engineering News, and the American Journal of Nursing.
Related EHP Article
Inorganic arsenic, a ubiquitous environmental toxicant, is well known for its harmful effects in humans, including cancer, diabetes, and cardiovascular disease.1 Organic forms of arsenic, such as monomethylarsonic acid (MMAV), are generally considered less toxic than inorganic arsenicals. Researchers report in this issue of EHP that certain bacteria in the human colon can promote the conversion of MMAV into the more toxic metabolite monomethyl monothioarsonic acid (MMMTAV).2
MMMTAV is what’s known as a thiolated arsenical; “thiolated” means it contains a sulfur group. Thiolated arsenicals can be up to 100 times more cytotoxic than their non-thiolated counterparts.3 MMMTAV and another thiolated metabolite, dimethyl monothioarsinic acid, have been detected in the urine of people who drank water contaminated with inorganic arsenic.4,5
Gut microbe cultures with a large proportion of sulfur-reducing bacteria produced significantly more of a toxic arsenic metabolite than nonenriched cultures. This could help explain why some individuals are especially sensitive to arsenic’s harmful effects.
© Shutterstock; DC.Rubin et al. (2014)2
The authors of the new study hypothesized that sulfur-reducing bacteria might be important for converting MMAV to a thiolated form. They tested their hypothesis using a Simulator of the Human Intestinal Microbial Ecosystem (SHIME), a device that mimics the digestive processes of the stomach, small intestine, and ascending, transverse, and descending portions of the colon. SHIME “is an in vitro tool that helps to mechanistically explain in vivo observations. You can tweak certain parameters while keeping others constant,” says team leader Tom Van de Wiele.
A series of experiments were performed using fecal samples reflecting a full complement of gut microbiota, samples in which sulfur-reducing bacteria were either enriched or suppressed, and pure cultures of Desulfovibrio desulfuricans (piger). The fecal samples were collected from 7 individuals, none of whom had taken antibiotics within the past 6 months.
The authors found that most arsenic biotransformation took place in the ascending and transverse colon. Hydrogen sulfide produced by gut bacteria drove this biotransformation; the addition of molybdate blocked hydrogen sulfide production and the conversion of MMAV to MMMTAV. Fecal microbiota from the 7 individuals produced varying amounts of hydrogen sulfide, which corresponded with variations in MMMTAV formation. Based on this evidence, the authors conclude that arsenic thiolation in the gut “can be considered a chemical process that requires a biological trigger, that is, sulfide production by metabolically active [sulfur-reducing bacteria].”2
The health consequences of the thiolated methylarsenicals produced in the gut remain unknown. “It’s an ‘orange flag,’ and one example of how certain microbial groups may contribute to increased toxicant risk,” says Van de Wiele. Numerous studies from the Human Microbiome Project have reported that the microbiome plays an integral role in human health.6 Similarly, toxicokinetics and pharmacokinetics also play important roles. “We cannot neglect these microbial processes,” says Van de Wiele.
Evaluating the potential risk of these compounds will not be a straightforward process; with an estimated 100 trillion microbes inhabiting the human gastrointestinal tract,7 the possible interactions with arsenic are endless. A first attempt could measure the conversion of MMAV to MMMTAV in human fecal samples. The results from the lowest and highest arsenic-converters may provide clues about how microbial processes control toxicant conversion, proposes Van de Wiele.
“The active involvement of sulfur-reducing bacteria in arsenic thiolation offers a novel intervention strategy to modulate arsenic metabolism by altering these bacteria,” says Kun Lu, an assistant professor at the University of Georgia, Athens, who was not involved with the study. Lu says the study also shows the clear impact of these bacteria on individual variability in thiolation, providing further insight into the role gut bacteria may play in individuals’ differing susceptibility to arsenic. Lu and colleagues have reported that infecting mice with Helicobacter trogontum, a potential cause of irritable bowel disease, changed not only the profile of the animals’ gut microbiomes but also the methylation and thiolation of arsenic metabolites excreted in urine.8
1. Hughes MF, et al. Arsenic exposure and toxicology: a historical perspective. Toxicol Sci 123(2):305–332 (2011); doi: 10.1093/toxsci/kfr184.
2. DC.Rubin SC, et al. Arsenic thiolation and the role of sulfate-reducing bacteria from the human intestinal tract. Environ Health Perspect 122(8):817–822 (2014); doi: 10.1289/ehp.1307759.
3. Ebert F, et al. Toxicological properties of the thiolated inorganic arsenic and arsenosugar metabolite thio-dimethylarsinic acid in human bladder cells. J Trace Elem Med Biol 28(2):138–146 (2014); doi: 10.1016/j.jtemb.2013.06.004.
4. Hansen HR, et al. Sulfur-containing arsenical mistaken for dimethylarsinous acid [DMA(III)] and identified as a natural metabolite in urine: major implications for studies on arsenic metabolism and toxicity. Chem Res Toxicol 17(8):1086–1091 (2004); doi: 10.1021/tx049978q.
5. Raml R, et al. Thio-dimethylarsinate is a common metabolite in urine samples from arsenic-exposed women in Bangladesh. Toxicol Appl Pharm 222(3):374–380 (2007); doi: 10.1016/j.taap.2006.12.014.
6. PLoS Collections: The Human Microbiome Project Collection (2012). San Francisco, CA:Public Library of Science. Available: http://www.ploscollections.org/hmp [accessed 25 June 2014].
7. Gill SR, et al. Metagenomic analysis of the human distal gut microbiome. Science 312(5778):1355–1359 (2006); doi: 10.1126/science.1124234.
8. Lu K, et al. Gut microbiome perturbations induced by bacterial infection affect arsenic biotransformation. Chem Res Toxicol 26(12):1893–1903 (2013); doi: 10.1021/tx4002868.
EHP is pleased to present the abstracts from the 29th Annual Scientific Conference of the International Society for Environmental Epidemiology (ISEE), held in Sydney, Australia, 24–28 September 2017. The conference was hosted by The University of Sydney and cosponsored by the Woolcock Institute of Medical Research, with the theme “Healthy Places, Healthy People—Where Are the Connections?”
We now offer expanded metrics on where EHP articles are being mentioned online! Be sure to check out the Altmetric badges where you see them on articles.